Home>>Signaling Pathways>> Others>>(-)-p-Bromotetramisole Oxalate

(-)-p-Bromotetramisole Oxalate (Synonyms: (-)-p-Bromotetramisole, L-para-Bromotetramisole)

Catalog No.GC14520

ALP inhibitor, potent and non-specific

Products are for research use only. Not for human use. We do not sell to patients.

(-)-p-Bromotetramisole Oxalate Chemical Structure

Cas No.: 62284-79-1

Size Price Stock Qty
10mM (in 1mL DMSO)
$40.00
In stock
10mg
$48.00
In stock
50mg
$121.00
In stock
500mg
$896.00
In stock
1g
$1,607.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1]:

Cell lines

neurosecretory PC12 cells

Preparation method

The solubility of this compound in DMSO is >18.7mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.3 mM

Applications

In neurosecretory PC12 cells, (-)-p-Bromotetramisole Oxalate significantly enhanced 5 μM ionomycin-stimulated [3H] NA release from PC12 cells. (-)-p-Bromotetramisole Oxalate alone only slightly stimulated [3H] NA release.

Animal experiment [2]:

Animal models

thyroparathyroidectomized Sprague-Dawley rats

Dosage form

systemic infusion at 0.8 ml/min of 10 mM (-)-p-Bromotetramisole Oxalate

Application

In thyroparathyroidectomized Sprague-Dawley rats, (-)-p-Bromotetramisole Oxalate significantly increased fractional excretion of phosphate (FEPi) from 4.7%±0.9% to 13.4%±3.1%.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Kitamura T, Murayama T, Nomura Y. Enhancement of Ca2+-induced noradrenaline release by vanadate in PC12 cells: possible involvement of tyrosine phosphorylation. Brain Res, 2000, 854(1-2): 165-171.

[2]. Onsgard-Meyer M, McCoy AL, Knox FG. Effect of bromotetramisole on renal phosphate excretion. Proc Soc Exp Biol Med, 1996, 213(2): 193-195.

Background

(-)-p-Bromotetramisole Oxalate (L-(-)-p-Bromotetramisole Oxalate, L-p-Bromotetramisole Oxalate, (-)-4-Bromotetramisole Oxalate) is a potent and non-specific inhibitor of alkaline phosphatase and is also an inhibitor of protein tyrosine phosphatases [1] [2].

Alkaline phosphatase is a hydrolase enzyme that removes phosphate groups from nucleotides, proteins and alkaloids. Protein tyrosine phosphatase is an enzyme that removes phosphate groups from phosphorylated tyrosine residues on target proteins.

(-)-p-Bromotetramisole Oxalate is an inhibitor of alkaline phosphatase and protein tyrosine phosphatases. In various rat tissues, (-)-p-Bromotetramisole Oxalate (0.1 μM) completely inhibited non-specific alkaline phosphatase [1]. In rat zona glomerulosa, (-)-p-Bromotetramisole Oxalate (100 μM) blocked the inhibition of Na+ pump (Na+, K+-ATPase) induced by angiotensin II. The result suggested that inhibition of the Na+ pump induced by angiotensin II might be mediated by a tyrosine phosphatase [2]. In neurosecretory PC12 cells, (-)-p-Bromotetramisole Oxalate (0.3 mM) increased ionomycin-stimulated noradrenaline (NA) release, which suggested that tyrosine phosphorylation regulated Ca2+-stimulated NA release [3].

In Sprague-Dawley rats, (-)-p-Bromotetramisole Oxalate (10 μM) significantly increased fractional excretion of phosphate (FEPi) from 4.7% to 13.4% [4].

References:
[1].  Borgers M, Thoné F. The inhibition of alkaline phosphatase by L-p-bromotetramisole. Histochemistry, 1975, 44(3): 277-280.
[2].  Yingst DR, Davis J, Schiebinger R. Inhibitors of tyrosine phosphatases block angiotensin II inhibition of Na(+) pump. Eur J Pharmacol, 2000, 406(1): 49-52.
[3].  Kitamura T, Murayama T, Nomura Y. Enhancement of Ca2+-induced noradrenaline release by vanadate in PC12 cells: possible involvement of tyrosine phosphorylation. Brain Res, 2000, 854(1-2): 165-171.
[4].  Onsgard-Meyer M, McCoy AL, Knox FG. Effect of bromotetramisole on renal phosphate excretion. Proc Soc Exp Biol Med, 1996, 213(2): 193-195.

Chemical Properties

Cas No. 62284-79-1 SDF
Synonyms (-)-p-Bromotetramisole, L-para-Bromotetramisole
Canonical SMILES BrC(C=C1)=CC=C1[C@H]2N=C3SCCN3C2.OC(C(O)=O)=O
Formula C13H13BrN2O4S M.Wt 373.22
Solubility ≥ 18.65mg/mL in DMSO Storage Desiccate at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.6794 mL 13.3969 mL 26.7938 mL
5 mM 0.5359 mL 2.6794 mL 5.3588 mL
10 mM 0.2679 mL 1.3397 mL 2.6794 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for (-)-p-Bromotetramisole Oxalate

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (-)-p-Bromotetramisole Oxalate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.